The Swiss pharma company Novartis ranks in the top 10 of pharma companies, and boasts drugs ranging from Ritalin and Lamisil to clozapine, Diovan and Gilenya. It also owns the generic giant Sandoz. Unlike its competitor, GlaxoSmithKline, Novartis did not offer free flu vaccines during the H1N1 flu epidemic.

In March 2011, Novartis gained FDA approval for Gilenya, its multiple sclerosis drug. The nod came on the heels of a narrower EMA approval, which grants second-line treatment status. According to experts, the drug could be worth $3 billion in annual sales as the first oral MS drug on the market.

Novartis purchased the remaining portion of eye care company Alcon in a $12.9 billion deal at the end of 2010, marking the end of one of the biggest battles in biopharma. Although many analysts predicted heavy layoffs in 2010 from the company, only 1,400 jobs were cut in December 2010, with the disclaimer that more could be on the way as Novartis, like others in the industry, analyzes its efficiency.

Tag:

Novartis

Latest Headlines

Latest Headlines

Novartis closes in on lucrative new Cosentyx use with ankylosing spondylitis results

Novartis has the first next-gen psoriasis med on the market in Cosentyx, and it's been spending money to take that first-to-market advantage as far as it can. But the Swiss drugmaker wants the treatment to be first in other indications, too. On that front, it got a boost on Wednesday with some new results in ankylosing spondylitis.

Does brand + generic really add up? Sandoz, Actavis execs count the ways

These days, companies are increasingly looking to put both branded and generic meds under one roof. And Peter Goldschmidt, the U.S. president of Novartis' Sandoz unit, doesn't know why they didn't do it sooner.

Top Novartis brass backs results-based drug pricing

Novartis CEO Joe Jimenez and Chairman Joerg Reinhardt sang the same tune on drug prices in separate interviews over the weekend, backing performance-based drug deals while pointing the finger at other healthcare expenses for driving up overall spending.

Novartis asks court to take the brakes off Neupogen biosim

Last month, a U.S. appeals court blocked Novartis' biosimilar version of Amgen's blockbuster Neupogen while the companies worked out a patent dispute. Unsurprisingly, though, Novartis wants that ban lifted, and now it's asking the court to do just that.

Novartis nixes another $600M buyout deal for Gamida Cell

Novartis won't be pulling the trigger on a $600 million buyout deal for Israel's Gamida Cell after all. Elbit Imaging, the majority owner of a minority stakeholder in the stem cell player, says that the pharma giant has decided not to pursue its option on the company, but has signaled its willingness to push ahead with their collaboration.

Roche unchallenged at top of cancer sellers, but Celgene could fight Novartis for No. 2

Roche has been at the top of the heap in oncology sales for years--and it's no wonder, what with its top-selling triumvirate, Herceptin, Rituxan and Avastin. The Swiss drugmaker racked up more than $25 billion in cancer last year, and its closest challenger, Novartis, managed less than half of that.

Roche, Novartis and Bayer snag NICE OKs

The U.K.'s cost-effectiveness gatekeeper, the National Institute for Health and Care Excellence (NICE), has bestowed its favor on a crop of new drugs, granting nods to contenders from Roche, Novartis and Bayer.

Novartis partners with 'robotic' pillmaker in oral biologic race

Biologic drugs for diseases like diabetes and rheumatoid arthritis remain injectable for now, but Rani Therapeutics' novel oral biologic delivery system just earned a partnership with pharma bigwig Novartis, suggesting that the San Jose startup is on the way to cracking the code.

Novartis rolls out 'life hacks' for MS patients with new Live Like You campaign

Novartis unveiled "life hacks" for multiple sclerosis patients, as part of a campaign commemorating World MS Day.

Post-swap Novartis preps cancer drug R&D road show

Two of the cancer drugs Novartis traded for from GSK--Tafinlar and Mekinist--will post combo survival data at ASCO.